Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-04
2007-12-04
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S332000
Reexamination Certificate
active
10639784
ABSTRACT:
Described herein are compounds that are useful as protein kinase inhibitors having the formulae I and V:or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, T, m, n, p, Q, Q′, R1, R2, Rx, R3, and R6are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
REFERENCES:
patent: 6949544 (2005-09-01), Bethiel et al.
patent: 2004/0147507 (2004-07-01), Ledeboer et al.
patent: 2004/0176271 (2004-09-01), Bethiel et al.
patent: WO 95/09847 (1995-04-01), None
patent: WO 95/09851 (1995-04-01), None
patent: WO 95/09853 (1995-04-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 99/65897 (1999-12-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO 02/20495 (2002-03-01), None
patent: WO 02/22601 (2002-03-01), None
patent: WO 02/46170 (2002-06-01), None
patent: WO 02/46171 (2002-06-01), None
patent: WO 02/46171 (2002-06-01), None
patent: WO 02/079193 (2002-10-01), None
patent: WO 02/079197 (2002-10-01), None
patent: WO 03/030909 (2003-04-01), None
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Casanova et al., PubMed Abstract (Rev Neurol 28(9):909-15) May 1999.
Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1 pp. 1004-1010, 1996.
Hardt et al., Glycogen Synthase Kinase-3beta A Novel Regulator of Cardiac Hypertrophy and Development, Circulation Research, 90:1055-1063, 2002.
Taxler, Protein Tyrosine Kinase inhibitors in cancer treatment, Exp. Opin. Ther. Patents, 7(6):571-588, 1997.
Chang et al., “Role of cAMP-dependent pathway in eosinophil apoptosis and survival,” Cell. Immunology, 203(1):29-38 (2000).
Frey et al., “TGF-beta regulation of mitogen-activated protein kinases in human breast cancer cells,” Cancer Letters, 177(1):41-50 (1997).
Fukunaga et al., “Role of MAP kinase in neurons,” Molecular Neurobiology, 16(1):79-95 (1998).
Hoshino et al., “Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors,” Oncogene, 18:813-22 (1999).
Hu et al., “Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord,” J. Neurochemistry, 85(2):432-42 (2003).
Illenberger et al. “The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease,” Molecular Biology of The Cell, 9(6):1495-512 (1998).
Kodama et al., “Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy,” Am. J. Physiol. Heart Circ. Physiol., 279(4):H1635-44 (2000).
Kortylewski et al., “Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells,” Biochemical Journal, 357(Pt 1):297-303 (2001).
Kyosseva et al., “Mitogen-activated protein kinases in schizophrenia,” Society of Biological Psychiatry, 46(5):689-96 (1999).
Lee et al., “ICAM-1-induced expression of proinflammatory cytokines in astrocytes: involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways,” The Journal of Immunology. 168(8):4658-66 (2000).
Namura et al., “Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia,” Proc. Natl. Acad. Sci. U.S.A. 98(20):11569-74 (2001).
Putz et al., “Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines,” Cancer Research, 59(1):227-33 (1999).
Raghunandan et al., “Hyperphosphorylation of the cytoskeletal protein Tau by the MAP-kinase PK40erk2: regulation by prior phosphorylation with cAMP-dependent protein kinase A,” Biochemical and Biophysical Research Communications, 215(3):1056-66 (1995).
Slevin et al., “Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke,” NeuroReport 11(12):2759-64 (2000).
Tack et al., “Autocrine activation of the IGF-1 signaling pathway in mesangial cells isolated from diabetic NOD mice,” Diabetes 51(1):182-8 (2002).
Takeishi et al., “Activation of mitogen-activated protein kinases and p60 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy,” Cardiovascular Research 53:131-137 (2002).
Pintucci et al., “Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells,” The FASEB Journal 16(2):598-600 (2002).
Moses, et al., “Injury-induced osteopontin gene expression in rat arterial smooth muscle cells in dependent on mitogen-activated protein kinases ERK1/ERK2,” Archives of Biochemistry and Biophysics 396(1):133-137 (2001).
Wersinger and Sidhu, “Inflammation and Parkinson's Disease,” Current Drug Targets, 1(3): 221-242 (2002).
Cochran John
Green Jeremy
Hale Michael R.
Ledford Brian
Maltais Francois
Pearson Daniel A.
Rao Deepak
Vertex Pharmaceuticals Incorporated
LandOfFree
Protein kinase inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase inhibitors and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3869194